Academic Journal
View in EDS

Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer.

Bibliographic Details
Title: Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer.
Authors: Pechacova Z; Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czechia, zdenka.pechacova@bulovka.cz., Lohynska R; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czechia., Spurkova Z; Department of Pathology and Anatomy, Bulovka University Hospital, Prague, Czechia., Sedivec V; Bioptical Laboratory Ltd, Pilsen, Czechia., Svajdler M; Bioptical Laboratory Ltd, Pilsen, Czechia., Drbohlavova T; Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czechia., Tesarova P; Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czechia., Pala M; Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czechia.
Source: Oncology [Oncology] 2026; Vol. 104 (9), pp. 1102-1114. Date of Electronic Publication: 2026 Mar 17.
Publication Type: Journal Article
Language: English
Journal Info: Publisher: Karger Country of Publication: Switzerland NLM ID: 0135054 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0232 (Electronic) Linking ISSN: 00302414 NLM ISO Abbreviation: Oncology Subsets: MEDLINE
Imprint Name(s): Original Publication: Basel, New York, Karger.
MeSH Terms: Ataxia Telangiectasia Mutated Proteins*/metabolism , MRE11 Homologue Protein*/metabolism , Laryngeal Neoplasms*/radiotherapy , Laryngeal Neoplasms*/pathology , Laryngeal Neoplasms*/metabolism , Laryngeal Neoplasms*/mortality, Biomarkers, Tumor/metabolism ; Humans ; Female ; Retrospective Studies ; Male ; Aged ; Middle Aged ; Treatment Outcome ; Immunohistochemistry ; Aged, 80 and over ; Adult ; Prognosis ; Neoplasm Staging
Abstract: <p>Introduction: Radiotherapy is a cornerstone of laryngeal cancer treatment. MRE11, a key component of the MRN complex, and the ATM protein are important elements of DNA repair. This study examines the impact of MRE11 and ATM on treatment outcomes in laryngeal cancer patients treated at Bulovka University Hospital in Prague.
Methods: This retrospective study included 108 patients with laryngeal cancer treated with radiotherapy. Immunohistochemical (IHC) analysis of pretreatment biopsy samples was performed to evaluate MRE11 and ATM expression and statistically estimate the impact on treatment outcomes.
Results: Statistically significant differences were found in subgroups of patients according to the IHC positivity of at least one of these two proteins. A statistically significant association was confirmed between IHC positivity for MRE11 or ATM protein (at least one of them) and better overall survival (OS; p < 0.001). IHC negativity for both proteins was found only in patients in clinical stage IV (p < 0.001) with the shortest OS confirmed in this subgroup of patients.
Conclusion: High IHC expression of MRE11 and ATM proteins was associated with earlier clinical stages and better treatment outcomes in laryngeal carcinoma, particularly when both proteins were elevated. The results point to the potential of MRE11 and ATM as predictors of treatment response, but more extensive molecular and clinical research would be needed to gain a more detailed insight. </p>.
(© 2026 The Author(s). Published by S. Karger AG, Basel.)
References: Cancer Res. 2010 Sep 15;70(18):7017-26. (PMID: 20843819)
Oncogene. 2021 May;40(20):3510-3532. (PMID: 33927349)
FEBS Lett. 2010 Sep 10;584(17):3675-81. (PMID: 20580718)
Mol Cancer. 2019 Nov 26;18(1):169. (PMID: 31767017)
Strahlenther Onkol. 2023 Oct;199(10):881-890. (PMID: 37042973)
Klin Onkol. 2022 Spring;35(2):119-127. (PMID: 35459336)
FEBS Lett. 2010 Sep 10;584(17):3682-95. (PMID: 20655309)
J Biol Chem. 2006 Apr 7;281(14):9346-50. (PMID: 16431910)
Ann Oncol. 2011 May;22(5):1088-1093. (PMID: 21127011)
J Stomatol Oral Maxillofac Surg. 2024 Oct;125(12 Suppl 2):101970. (PMID: 39032645)
CA Cancer J Clin. 2017 Jan;67(1):31-50. (PMID: 27898173)
Sci Rep. 2022 Oct 12;12(1):17051. (PMID: 36224266)
Cancers (Basel). 2020 Dec 16;12(12):. (PMID: 33339169)
J Pers Med. 2021 May 10;11(5):. (PMID: 34068585)
Recent Results Cancer Res. 2016;198:1-24. (PMID: 27318679)
Laryngoscope. 2014 Jan;124(1):179-87. (PMID: 23775802)
Front Oncol. 2020 Jan 17;9:1465. (PMID: 32010608)
J Clin Med. 2025 May 12;14(10):. (PMID: 40429363)
J Natl Compr Canc Netw. 2008 Aug;6(7):646-95. (PMID: 18691457)
Signal Transduct Target Ther. 2025 Feb 17;10(1):42. (PMID: 39956859)
Cancers (Basel). 2023 Oct 13;15(20):. (PMID: 37894339)
Front Oncol. 2022 Jun 22;12:949139. (PMID: 35814397)
Contributed Indexing: Keywords: ATM Protein; Biomarker; Laryngeal cancer; MRE11 Homolog; Radiotherapy
Substance Nomenclature: EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
EC 3.1.- (MRE11 Homologue Protein)
0 (MRE11 protein, human)
EC 2.7.11.1 (ATM protein, human)
0 (Biomarkers, Tumor)
Entry Date(s): Date Created: 20260317 Date Completed: 20261007 Latest Revision: 20261009
Update Code: 20261009
PubMed Central ID: PMC13186548
DOI: 10.1159/000551450
PMID: 41843733
Database: MEDLINE
Description
ISSN:1423-0232
DOI:10.1159/000551450